<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04933591</url>
  </required_header>
  <id_info>
    <org_study_id>NIS-ВЕН-19.03</org_study_id>
    <nct_id>NCT04933591</nct_id>
  </id_info>
  <brief_title>Impact of Treatment With VENARUS® on the Level of Monocyte Chemoattractant Protein 1 in Varicose Veins Blood</brief_title>
  <official_title>Impact of Treatment With VENARUS® on Vein-specific by Determining the Level of Monocyte Chemoattractant Protein 1 in Varicose Veins Blood</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pirogov Russian National Research Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pirogov Russian National Research Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to find if the venoactive drug contained diosmin and hesperidin is&#xD;
      able to work against chronic vein-specific inflammation by changing the level of Monocyte&#xD;
      Chemoattractant Protein 1. This chemokine is involved in the vein wall remodeling in patients&#xD;
      with lower limb varicose veins.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a post-registration open-label observational prospective single-center study&#xD;
      with minimal intervention. Individuals aged 18-50 with varicose veins and CEAP C2-C4, Ep, As,&#xD;
      Pr will be invited to participate in the study.&#xD;
&#xD;
      Those who agree, will be examined both clinically and by duplex ultrasound. Medical history&#xD;
      of participants will be taken, demographic data will be collected. Blood will be drawn from&#xD;
      the varicose vein of the affected limb. Discomfort in the affected limb will be evaluated by&#xD;
      a visual-analog scale. Duplex ultrasound will be used in every resident to reveal&#xD;
      pathological venous reflux in deep and superficial veins.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2020</start_date>
  <completion_date type="Anticipated">September 28, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 28, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in the level of Monocyte Chemoattractant Protein 1 level in blood taken from varocse vein</measure>
    <time_frame>2 months</time_frame>
    <description>Blood samples will be taken from varicose veins and level of cytokine Monocyte Chemoattractant Protein 1 will be measured by immunofluorescence. After 2 months measurement will be repeated and the change will be registered.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of discomfort related to symptoms of varicose veins (i.e., pain, heaviness, etc.)</measure>
    <time_frame>2 months</time_frame>
    <description>Discomfort will be measured by visual-analogue scale. After 2 months measurement will be repeated and the change will be registered.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Varicose Veins</condition>
  <arm_group>
    <arm_group_label>study group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Individuals aged 18-50 with varicose veins and CEAP C2-C4, Ep, As, Pr. Clinical and ultrasound examinations will be used to confirm varicose veins disease. It is planned to take blood samples from a varicose vein before and after administration of Venarus® (100 mg hesperidin + 900 mg diosmin) for 2 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Individuals aged 18-50 with varicose veins and CEAP C2-C4, Ep, As, Pr vein. Clinical and ultrasound examinations will be used to confirm varicose veins disease. It is planned to take blood samples from a varicose vein at inclusion and 2 months later/</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diosmin / Hesperidin</intervention_name>
    <description>Venoactive drugs are used for patients with varicose veins as a tool for alleviating symptoms</description>
    <arm_group_label>study group</arm_group_label>
    <other_name>Venoactive drug</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  • both female and male&#xD;
&#xD;
               -  age from 18 to 50 years old&#xD;
&#xD;
               -  Verified diagnosis of chronic venous insufficiency CEAP C2-C4&#xD;
&#xD;
               -  signed infromed consent&#xD;
&#xD;
               -  Absence of any other treatment 2 weeks before the start of the study and&#xD;
                  throughout the duration of the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  • age less than 18 and more than 50 years&#xD;
&#xD;
               -  Previously performed invasive interventions for varicose veins on any of the&#xD;
                  lower extremities&#xD;
&#xD;
               -  No visible varicose veins&#xD;
&#xD;
               -  Thrombophlebitis and deep vein thrombosis of the lower extremities in the past&#xD;
&#xD;
               -  Taking prohibited pre-trial therapy&#xD;
&#xD;
               -  Contraindications to taking Venarus®&#xD;
&#xD;
               -  not signed informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Igor Zolotukhin, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pirogov Russian National Research Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Igor Zolotukhin, PhD</last_name>
    <phone>+79255182479</phone>
    <email>zoloto70@bk.ru</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Olga Golovanova, PhD</last_name>
    <phone>+79166515924</phone>
    <email>ovgolovanova@mail.ru</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Pirogov Russian National Research Medical University</name>
      <address>
        <city>Moscow</city>
        <zip>117997</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Igor Zolotukhin</last_name>
      <phone>+79255182479</phone>
      <email>zoloto70@bk.ru</email>
    </contact>
    <contact_backup>
      <last_name>Olga Golovanova</last_name>
      <phone>+79166515934</phone>
      <email>ovgolovanova@mail.ru</email>
    </contact_backup>
    <investigator>
      <last_name>Igor Zolotukhin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 7, 2021</study_first_submitted>
  <study_first_submitted_qc>June 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 22, 2021</study_first_posted>
  <last_update_submitted>June 13, 2021</last_update_submitted>
  <last_update_submitted_qc>June 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Pirogov Russian National Research Medical University</investigator_affiliation>
    <investigator_full_name>Igor Zolotukhin</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Varicose Veins</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

